comparemela.com

Latest Breaking News On - Dupilumab - Page 1 : comparemela.com

FDA Accepts sBLA for Priority Review of Dupilumab for Uncontrolled COPD

The FDA’s decision is planned for June 2024, and follows the successful results of the BOREAS and NOTUS trials.

Drug-administration
Biologics-license-application
Priority-review
Esbla
Fda
Copd
Uncontrolled
Pulmonary
Dupilumab
Dupixent

Abrocitinib Effective for Eczema Patients with Inadequate Response to Upadacitinib, Dupilumab

This research also included results from a sub-analysis of non-responders with hand eczema to dupilumab and upadacitinib.

Netherlands
Groningen
University-medical-center-groningen
Dutch-bioday
Investigator-global-assessment
Eczema-area
Severity-index
Hand-eczema-severity-index
Eczema
Atopic-dermatitis
Sad

Study: Tralokinumab Shows More Frequent Injection Site Reactions Than Dupilumab in Patients With AD

Although injection site reactions were common occurrences in both the tralokinumab and dupilumab groups, tralokinumab caused ISRs more frequently.

Italy
Image-credit
Dermatology-unit
Naples-federico
Numerical-rating-scale
Atopic-dermatitis
Dupilumab
Tralokinumab
Injection-site-reactions

Combination Dupilumab, Topical Corticosteroids Treatment Demonstrated Efficacy in Children With AD

Dupilumab and topical corticosteroids can be used to treat symptoms in children with atopic dermatitis (AD).

Image-credit
Eczema-area
Severity-index
Dermatology-life-quality-index
Global-assessment
Cochrane-handbook
Systemic-reviews
Interventions-risk
Bias-tool
Atopic-dermatitis
Dupilumab

Gastroenterology Month in Review: January 2024

Our January 2024 Month in Review spotlights the FDA approval of a new indication of dupilumab (Dupixent) for pediatric eosinophilic esophagitis, new clinical trial data, and research about the prevention and management of IBD.

Evan-dellon
Dupilumab-dupixent
Julie-khlevner
Drug-administration
University-of-north-carolina-chapel-hill
Contemporary-pediatric
Esophageal-diseases
North-carolina-chapel-hill
Pediatric-gastrointestinal-motility-center
Columbia-university-medical-center
Ibd
Inflammatory-bowel-disease

vimarsana © 2020. All Rights Reserved.